Patent intelligence · US
US 8987228
Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis
Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(…
Patent details — US 8987228
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 24, 2015
- Expiration
- Mar 19, 2035
- Applicant
- CAN-FITE BIOPHARMA LTD.
- Claims
- 12
- CPC classes
- A61K, A61K31/7076, A61P, A61P17/06
Quick answer
US 8987228 (Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis) is held by CAN-FITE BIOPHARMA LTD.. Status: granted. Granted Mar 24, 2015. Expires Mar 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAN-FITE BIOPHARMA LTD.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/7076, A61P, A61P17/06
More from CAN-FITE BIOPHARMA LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12213990
A3 adenosine receptor ligand for use for achieving a fat loss effect
granted -
US 11291681
Method for treating fibrotic liver tissue using Cl-IB-MECA
granted -
US 10780106
Method for treating NASH accompanied by fibrosis using Cl-IB-MECA
granted -
US 10265337
Use of A3 adenosine receptor agonist in osteoarthritis treatment
granted -
US 9549943
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
granted -
US 9387220
Method for inducing hepatocyte proliferation and uses thereof
granted -
US 9102698
Process for the synthesis of IB-MECA
granted
Frequently asked questions
What is US patent 8987228?
US 8987228 (Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis) is held by CAN-FITE BIOPHARMA LTD.. Status: granted. Granted Mar 24, 2015. Expires Mar 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8987228?
CAN-FITE BIOPHARMA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 8987228 expire?
Our index shows an expiration date of Mar 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.